Drug Res (Stuttg) 2013; 63(09): 489-494
DOI: 10.1055/s-0033-1347189
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics and Relative Bioavailability Evaluation of Linezolid Suspension and Tablet Formulations

S. A. Helmy
1   Department of Pharmaceutics and Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
› Institutsangaben
Weitere Informationen


received 03. April 2013

accepted 01. Mai 2013

05. Juni 2013 (online)


The oral liquid formulations poses an alternative way in providing medications to pediatric patients, geriatric patients, patients with feeding tubes, and patients who cannot swallow solid dosage forms. This study was conducted to evaluate the pharmacokinetics (PKs) and relative bioavailability of suspension (reference) and tablet (test) formulations of Linezolid (LZD). In vivo study was established according to a single-center, randomized, single-dose, laboratory-blinded, 2 Way, Cross-Over Study with a washout period of 1-week. Under fasting conditions, 28 healthy Egyptian male volunteers were randomly allocated to receive a single oral dose of either 30 ml LZD or 1 tablet (600 mg LZD) of marketed suspension and tablet formulations. Plasma samples were obtained over a 48-h interval and analyzed for LZD by reversed phase liquid chromatography with ultraviolet detection. The 90% confidence intervals for the ratio of log transformed values of Cmax, AUC0-t, and AUCt-∞ of the two treatments were within the acceptable range (0.8–1.25) for bioequivalence. From PK perspectives, in this small study in healthy Egyptian adult male volunteers, a single 600 mg dose of the tablet formulation demonstrated comparable rate and extent of absorption to a single 600 mg dose of the suspension formulation based on the US FDA’s regulatory definition. No adverse events occurred or were reported after a single 600 mg LZD and both formulations were well tolerated.

  • References

  • 1 Clemett D, Markham A. Linezolid. Drugs 2000; 59: 815-827
  • 2 Daly JS, Eliopoulos GM, Willey S et al. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother 1988; 32: 1341-1346
  • 3 Welshman IR, Stalker DI, Wajsczuk CP. Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailability of linezolid. Anti-Infect Drugs Chemother 1998; 16 (Suppl. 01) 54
  • 4 Stalker DJ, Jungbluth GL, Hopkins NK et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003; 51: 1239-1246
  • 5 Gee T, Ellis R, Marshall G et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45: 1843-1845
  • 6 Slatter JG, Stalker DJ, Feenstra KL et al. Pharmacokinetics, metabolism and excretion of linezolid following an oral dose of 14C linezolid to healthy human subjects. Drug Metab Dispos 2001; 29: 1136-1145
  • 7 Cattaneo D, Baldelli S, Conti F et al. Determination of Linezolid in Human Plasma by High Performance Liquid Chromatography with Ultraviolet Detection. Ther Drug Monit 2010; 32: 520-524
  • 8 Zyvox® Investigational Medicinal Product Last revision July 2008. Available at http://media.pfizer.com/files/products/uspi_zyvox.pdf [Accessed September 10, 2009]
  • 9 Peng GW, Stryd RP, Murata S et al. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 1999; 20: 65-73
  • 10 Ehrlich M, Trittler R, Daschner FD et al. A new and rapid method for monitoring the new oxazolidinone antibiotic linezolid in serum and urine by high performance liquid chromatography-integrated sample preparation. J Chromatogr B Biomed Sci Appl 2001; 755: 373-377
  • 11 Tobin CM, Sunderland J, White LO et al. A simple, isocratic highperformance liquid chromatography assay for linezolid in human serum. J Antimicrob Chemother 2001; 48: 605-608
  • 12 Toutain J, Boselli E, Djabarouti S et al. Determination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 145-150
  • 13 Boak LM, Li J, Nation RL et al. High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma. Biomed Chromatogr 2006; 20: 782-786
  • 14 Swoboda S, Ober M, Anagnostakos K et al. A simple isocratic HPLC assay to determine linezolid concentrations in different biomatrices for in vivo and in vitro studies. Clin Chem Lab Med 2007; 45: 1019-1022
  • 15 Cavazos-Rocha N, Vera-Cabrera L, Welsh-Lozano O et al. Simultaneous determination and validation of antimicrobials in plasma and tissue of actinomycetoma by high-performance liquid chromatography with diode array and fluorescence detection. J Pharm Biomed Anal 2007; 43: 1775-1781
  • 16 Baietto L, D’Avolio A, De Rosa FG et al. Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV. Ther Drug Monit 2009; 31: 104-109
  • 17 Borner K, Borner E, Lode H. Determination of linezolid in human serum and urine by high-performance liquid chromatography. Int J Antimicrob Agents 2001; 18: 253-258
  • 18 Phillips OA, Abdel-Hamid ME, al-Hassawi NA. Determination of linezolid in human plasma by LC-MS-MS. Analyst 2001; 126: 609-614
  • 19 la Marca G, Villanelli F, Malvagia S et al. Rapid and sensitive LC-MS/MS method for the analysis of antibiotic linezolid on dried blood spot. J Pharm Biomed Anal 2012; 67-68: 86-91
  • 20 US Dept of Health and Human Services (HHS), Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry. Bioanalytical method validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM070107.pdf [Accessed November 13, 2008]
  • 21 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. August 2010 www.ich.org/fileadmin/Public_Web_Site/ICH…/E2F_Step_4.pdf [Last Accessed January 5, 2013]
  • 22 Gibaldi M, Perrier D. “Pharmacokinetics”. Swarbrick J. Ed. Informa Healthcare USA, Inc; New York, USA: 1982
  • 23 Hedaya MA. “Basic pharmacokinetics”. 1st Ed. Taylor and Francis group; Boca Raton, FL, USA: 2007
  • 24 Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1992; 30 (Suppl. 01) S51-S58
  • 25 SAS Institute Inc. SAS/STAT User’s guide, Version 6. 4th Edition Vol. 2 SAS Institute; Cary, NC: 1990
  • 26 Locke S. An exact confidence interval from untransformed data for the ratio of two formulations means. J Pharmacokinet Biopharm 1984; 12: 649-655
  • 27 Tsuji Y, Hiraki Y, Mizoguchi A et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother 2008; 14: 156-160